Profil
Jens Bjørheim currently works at Zelluna ASA, as Chief Medical Officer.
Dr. Bjørheim also formerly worked at Pronova BioPharma ASA, as Medical Director from 2006 to 2008, AstraZeneca A, as Senior Medical Director-Oncology from 2013 to 2016, and Ultimovacs ASA, as Chief Medical Officer.
Dr. Bjørheim received his doctorate degree in 1999 from the University of Oslo and doctorate degree in 2003 from the University of Oslo.
Aktiva positioner av Jens Bjørheim
| Företag | Position | Start |
|---|
Tidigare kända positioner av Jens Bjørheim
| Företag | Position | Slut |
|---|---|---|
AstraZeneca A/S (Denmark)
AstraZeneca A/S (Denmark) Pharmaceuticals: MajorHealth Technology Develops and distributes pharmaceutical medicines | Företagsledare/Principal | 2016-01-01 |
Pronova BioPharma ASA
Pronova BioPharma ASA Pharmaceuticals: OtherHealth Technology Develops, manufactures and markets omega-3-derived pharmaceuticals | Teknisk/Vetenskaplig/F&U Direktör | 2008-01-01 |
Ultimovacs ASA
Ultimovacs ASA Pharmaceuticals: MajorHealth Technology Develops novel peptide based therapeutic cancer vaccine | Teknisk/Vetenskaplig/F&U Direktör | - |
Jens Bjørheims utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 4 |
|---|---|
Pronova BioPharma ASA
Pronova BioPharma ASA Pharmaceuticals: OtherHealth Technology Develops, manufactures and markets omega-3-derived pharmaceuticals | Health Technology |
University of Oslo
University of Oslo Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AstraZeneca A/S (Denmark)
AstraZeneca A/S (Denmark) Pharmaceuticals: MajorHealth Technology Develops and distributes pharmaceutical medicines | Health Technology |
Ultimovacs ASA
Ultimovacs ASA Pharmaceuticals: MajorHealth Technology Develops novel peptide based therapeutic cancer vaccine | Health Technology |
















